How incretin therapy changes diabetes and prediabetes management
May 22, 2017VBWG ACC 2017 Dr. Rajagopalan considers how the emergence of GLP-1 agonists, DPP-4 inhibitors and SGLT2 inhibitors has caused a sea change in the mangement of diabetes towards a broader approach to address CV risk.
Educational information
This video was recorded after the Vascular Biology Working Group Meeting at ACC 2017, in Washington, DC, USA.
PACE-cme did not receive financial support for the production of this video.
Faculty & Disclosures
Sanjay Rajagopalan, MD - Case Western Reserve School of Medicine, Cleveland, OH, USA